Preliminary Findings of mRNA COVID-19 Vaccine Safety in Pregnant Persons
Tom T. Shimabukuro, Shin Y. Kim, Tanya R. Myers, Pedro L. Moro, Titilope Oduyebo, Lakshmi Panagiotakopoulos, Paige Marquez, Christine K. Olson, Ruiling Liu, Karen Chang, Sascha Ellington, Veronica Burkel, Ashley N. Smoots, Caitlin J. Green, Charles Licata, Bicheng C. Zhang, Meghna Alimchandani, Adamma Mba‐Jonas, Stacey W. Martin, Julianne Gee, Dana Meaney‐Delman
Abstract
(Abstracted from N Engl J Med 2021;384:2273–2282) The first coronavirus disease (COVID-19) vaccines in the United States were the messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). Pregnant persons were excluded from the original Emergency Use Authorization (EUA) issued by the Federal Drug Administration (FDA) in December 2020.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)AuthorizationVirologyFood and drug administrationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Messenger RNA2019-20 coronavirus outbreakMedical emergencyDiseaseInfectious disease (medical specialty)Internal medicineOutbreakComputer securityGeneBiochemistryChemistryComputer scienceCOVID-19 Impact on Reproduction